The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the chemotherapy of exercise-induced asthma. It has also been used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid. Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma because most exacerbations of this condition involve respiratory virus infection-triggered inflammatory mechanisms which, to a large extent, involve airway epithelial cell/neutrophil interactions. The primary objective of this review is to evaluate the role of montelukast in the treatment of intermittent asthma in children.
Introduction
About 300 million of the world's population is affected by asthma, 1 which is the most common chronic disease in children. By definition "asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway hyper-responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread, but variable, airway obstruction, that is often reversible either spontaneously or with treatment". 2 In children, especially those younger than five years of age (pre-school), the diagnosis and treatment of asthma may be challenging. Children are often excluded from clinical trials of available treatments, while lung function tests are difficult or impossible to perform. Furthermore, published reports often do not distinguish asthma from other causes of wheezing.
Although the new GINA guideline no longer focuses on asthma severity, but rather targets asthma control, 2 the initial assessment and treatment plan of the patient will be guided by symptom severity and a consideration of whether the asthma is persistent or intermittent. The four categories of asthma stated are: i) intermittent; ii) mild persistent; iii) moderate persistent; and iv) severe persistent.
In the case of intermittent asthma in children, acute exacerbations and bronchoconstriction are often followed by lengthy symptom-free periods which persist for several weeks, or even months. The exacerbations are often severe, being triggered by viral infections, exercise, or exposure to allergens, resulting in bronchoconstriction, either in isolation, or together with symptoms of allergic rhinitis. A cautious approach to treatment is necessary in these patients. The need for controller medication in the form of inhaled corticosteroids (ICS), oral corticosteroids, or leukotriene receptor antagonists (LTRAs) has been advocated in a number of studies. 3, 4 In the GINA guideline, the use of LTRAs is recommended either as an alternative controller therapy to ICS in mild persistent asthma, or as add-on therapy to other controller medications in patients with moderate-to-severe asthma. 2 The Paediatric Consensus Report (PRACTALL) 5 identifies specific paediatric indications for the use of LTRAs as monotherapy.
Montelukast is the only LTRA approved for use in the paediatric age range.
In this review, our primary objective is to evaluate the role of montelukast in the treatment of intermittent (episodic) asthma in children, with emphasis on mode of therapeutic action, metabolism and pharmacokinetics, safety, and efficacy. Of necessity, this is preceded by a consideration of the clinical spectrum and underlying inflammatory mechanisms associated with intermittent asthma.
Clinical Spectrum and Inflammatory Mechanisms in Intermittent Asthma
The clinical manifestations of intermittent asthma in children include recurrent episodes of cough, wheezing or dyspnea. However, asthma must be distinguished from numerous other causes of episodic cough or wheezing 6 (Table 1) as the therapy and outcome of these conditions may vary. Of these, viral-induced wheezing (VIW) is important, especially in pre-school children who are at high risk for recurrent viral infections of the upper and lower airways.
Mild intermittent asthma, although characterized by infrequent symptoms and normal lung function, is associated with chronic airway inflammation which may result in irreversible airflow limitation if left unattended. 7 In contra-distinction to VIW, airway inflammation in intermittent asthma is characterized by the presence of eosinophils, macrophages, and T-lymphocytes, compatible with eosinophilic inflammation. 8 However, the eosinophils are fewer in number and are in a less activated state than those in the airways of individuals with persistent asthma. 8 Allergen exposure, understandably, is a trigger for asthma attacks in children with intermittent asthma. However, respiratory virus infection is the major precipitant of acute exacerbations in this group. 9 Viral infections have been implicated not only as triggers of acute asthma exacerbations, but also as inducers of the persistent airway inflammation typical of asthma. In contra-distinction to allergen-induced (atopic) asthma, bronchial epithelial cells, which are the primary targets of viral infection and replication, appear to initiate the airway inflammation responsible for acute exacerbations of intermittent asthma. Following exposure to respiratory viruses, these cells produce an array of pro-inflammatory chemokines/ cytokines and bioactive lipid mediators such as leukotrienes (LT) B 4 and C 4 . 9 These, in turn, recruit neutrophils, eosinophils, mast cells, monocytes, B-cells and T-cells to the airways, intensifying airway inflammation. 9 It is now apparent that bronchial epithelial cells and neutrophils are critically involved in causing the airway inflammation triggered by respiratory virus infection. Importantly, both cell types are relatively resistant to the anti-inflammatory actions of corticosteroids, with, in the case of bronchial epithelial cells, resistance being potentiated by hypoxia. 10 The production of IL-17A by airway Th17 cells may also favor superimposition of neutrophilic on eosinophilic inflammation. This cytokine has been reported to trigger the production of the potent neutrophil chemoattractant, IL-8, by human rhinovirus-infected bronchial epithelial cells in the setting of down-regulation of production of the eosinophil chemoattractant, RANTES. 11 Interestingly, children with idiopathic neutropenia appear to be protected from the development of recurrent episodes of wheezing. 12 Similar corticosteroid-insensitive, pro-inflammatory mechanisms appear to underpin respiratory virus infection-associated bronchiolitis and wheeze in nonatopic children, 13 underscoring the importance of effective, neutrophil-directed chemotherapeutic strategies in both conditions. Importantly, as described below, leukotriene receptor antagonists (LTRAs) such as montelukast, have broad-spectrum anti-inflammatory properties, including downregulation of neutrophil pro-inflammatory activity, which suggests that LTRAs may be more appropriate for inflammatory responses that are neutrophil-dependent.
The role of LTRAs in the treatment of intermittent asthma cannot be considered without reference to the types of airway inflammation associated with this form of asthma as discussed above. The cells and their pro-inflammatory mediators which promote airway inflammation in asthma, as well as the effects of montelukast on these are represented schematically in Figure 1 . The complexity of cytokine and chemokine interactions during this process probably accounts for the limited success of therapies targeting single mediators which can be overcome by alternative proinflammatory pathways. Therefore, broad-spectrum anti-inflammatory agents such as corticosteroids and montelukast are likely to be of much greater benefit. The extended spectrum of anti-inflammatory activity of montelukast depicted in Figure 1 is discussed below.
Mechanisms of Action of Montelukast
Montelukast is a prototype, selective, pharmacological antagonist of type 1 cysteinyl leukotriene receptors (Cys LT 1 Rs). These are G-protein-coupled receptors that recognize the CysLTs, LTD 4 and LTC 4 /LTE 4 in a decreasing order of affinity. 14 CysLT 1 Rs have a relatively restricted occurrence, being expressed on the plasma membrane of structural cells and inflammatory cells. In the case of the former, interaction of CysLTs with CysLT 1 Rs on epithelial cells, fibroblasts/ myoblasts, smooth muscle cells, and endothelial cells, results in respective increases in the following pro-asthmatic activities: i) mucus secretion and goblet cells; ii) collagen synthesis and release, with implications for airway re-modeling; iii) contractility and proliferation; and iv) vascular permeability and edema. 14 In the case of inflammatory cells, CysLT 1 Rs are expressed on neutrophils, monocytes/macrophages, basophils, mast cells, dendritic cells, B lymphocytes, and CD4 + T cells. However, only mast cells, basophils, eosinophils, and to a lesser extent monocytes/macrophages, possess the necessary enzymes for conversion of LTA 4 to CysLTs. Following their interaction with CysLT 1 Rs on target cells, CysLTs exacerbate the allergic/inflammatory reaction by: i) recruiting and activating T H 2 cells and eosinophils; ii) increasing the production of reactive oxidant species by neutrophils, eosinophils, and monocytes/ macrophages, these oxidants being mediators of vascular permeability and bronchial hyper-reactivity; and iii) inducing the release of proteolytic enzymes such as Clinical Medicine Reviews in Therapeutics 2010:2
Airway
Epithelial cells elastase and matrix metalloproteinases from phagocytic cells, which in turn promote airway re-modeling. [14] [15] [16] [17] All of these pro-asthmatic/pro-inflammatory activities of CysLTs are effectively antagonized by montelukast, this being the primary mode of therapeutic action of this anti-asthmatic agent. Interestingly, however, several recent studies have revealed that montelukast possesses a range of secondary anti-inflammatory activities, which are apparently unrelated to conventional Cys-LT 1 R antagonism. These include the following:
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• Inhibition of the enzyme 5-lipoxygenase by a mechanism which has not been fully characte rized. [18] [19] [20] Importantly, these inhibitory effects of montelukast on 5-lipoxygenase activity in activated neutrophils and monocytes are detectable at pharmacologically relevant concentrations of this agent and result in decreased synthesis not only of CysLTs, but also of LTB 4 , a potent activator of, and chemoattractant for neutrophils, monocytes/ macrophages, mast-cells and T cells. 14 Inhibition of synthesis of CysLTs clearly complements montelukast-mediated antagonism of CysLT 1 Rs, while attenuation of production of LTB 4 represents a potentially important additional therapeutic activity which may contribute to the control of neutrophilmediated inflammation. It is noteworthy that LTB 4 has been implicated in the development of inflammation in allergic diseases, particularly those which are poorly responsive to corticosteroids in which the neutrophil may be major culprit. 21, 22 • Non-specific inhibition of cyclic nucleotide phosphodiesterases in neutrophils, and presumably other types of immune and inflammatory cells, leading to increased intracellular levels of adenosine 3′, 5′ cyclic monophosphate (cAMP), which has potent broad-spectrum anti-inflammatory properties. 19 At concentrations which are within, or moderately above the peak therapeutic serum concentrations, montelukast was found to inhibit the production of reactive oxygen species and release of the primary granule protease, elastase, by activated neutrophils by a cAMP-dependent mechanism. Importantly, cAMP has also been reported to inhibit 5-lipoxygenase and LTB 4 synthesis by activated neutrophils, 23 a mechanism which may underpin the inhibitory effects of montelukast on this enzyme. • Inhibition of the adherence of eosinophils to vascular endothelium by interfering with the interaction of the eosinophil adhesion molecule, α 4 β1, with its counter-receptor, vascular cell adhesion molecule-1. 24 These anti-inflammatory effects of montelukast were detected at therapeutically relevant concentrations of this agent and may restrict eosinophil-mediated inflammation in asthma.
If operative in the clinical setting, these secondary anti-inflammatory properties of montelukast are likely to complement the primary CysLT 1 R-directed antiasthmatic/anti-inflammatory activities of this agent by targeting additional inflammatory cell types and their mediators, especially the corticosteroid-resistant neutrophil. Montelukast may therefore possess anti-inflammatory properties which have a broader spectrum than originally thought, making this agent potentially useful in the treatment of intermittent asthma.
Metabolism and Pharmacokinetic Profile Absorption
Singulair (montelukast), manufactured by Merck (Merck Research Laboratories, Rahway, NJ, USA), is a popular LTRA, however its effectiveness and blood levels may vary between individuals. 25 It is likely that membrane efflux and uptake transporters mediate the absorption of the drug into the systemic circulation following oral administration. The efflux and uptake transporters may be influenced by genetic variability that could contribute to the observed heterogeneity in response. 25 Mougey et al investigated the possible carrier-mediated uptake of montelukast and showed that the permeability of this drug has an activation energy of 13.7 ± 0.7 kcal/mol, consistent with carrier-mediated transport (4 kcal/mole for passive diffusion). 26 A MDCKII cell line expressing OATP2B1, a membrane transport protein, (coded for by the SLCO2B1 gene), displayed significantly increased permeability of montelukast. Genetic variation of this transport protein was associated with variable montelukast plasma concentrations and variable response to treatment in patients with asthma. 26 Singulair is rapidly absorbed, primarily in the intestine, following oral administration of the drug. According to the manufacturer, the mean peak montelukast plasma concentration is achieved at 3-4 hours after administration of a 10 milligram (mg) film-coated tablet (FCT) to fasted adults, at 2-2.5 hours after administration of a 5 mg chewable tablet to fasted adults, at 2 hours after administration of a 4 mg chewable tablet to pediatric patients 2 to 5 years of age in the fasted state, while the 4 mg granule formulation is bioequivalent to the 4 mg chewable tablet when administered to adults in the fasted state. The mean oral bioavailabilities are 64%, 73%, 63% for those taking the 10 mg film coated tablets, the 5 mg chewable tablet and the 4 mg chewable tablet, respectively. 27 Clinical Medicine Reviews in Therapeutics 2010:2
Distribution
Distribution of montelukast in body tissues and fluids has not been fully characterized. The steady-state volume of distribution of montelukast is 8-11 L. Montelukast is more than 99% bound to plasma proteins. Studies in rats, using radiolabeled montelukast, indicated minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24 hours post-administration were minimal in all other tissues.
Metabolism
Montelukast is extensively metabolized. In studies using therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and pediatric patients. 27 In vitro studies, using human liver microsomes, indicated that cytochromes P450, 3A4 and 2C9 are involved in the metabolism of montelukast. 28 No significant difference in montelukast metabolism was found between pediatric (ages 6-11) and adult (ages 50-65) subjects. 28 Since montelukast is metabolized by CYP3A4, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP3A4, such as phenytoin, phenobarbital and rifampicin. 27 elimination Biliary excretion is the predominant pathway for the elimination of montelukast and its metabolites. Urinary excretion is insignificant, and thus dose adjustments in renally compromised patients would not be necessary. 29 
Plasma concentrations in adults and children
The maximum plasma concentration (Cmax) after orally administered montelukast at a dose of 10 mg, ranged from 350-385 ng/ml in healthy male and female subjects, while age had little or no effect when the pharmacokinetic profile of the elderly was compared to that of young adults. 30, 31 Administration of 4 mg chewable tablets or 10 mg FCT to children aged 2-5 years and adults respectively, resulted in a similar AUCpop (area under the curve), while the respective Cmax values were 471 ng/ml in the children and 283 ng/ml in adults. 32 A study indicated that a single dose of montelukast (4 mg oral granules) administered to children 3-6 months of age 33 yielded systemic exposures similar to those observed in children aged 6-24 months. 34 The respective maximum plasma concentrations were 561.1 ng/ml and 514.4 ng/ml. 33, 34 The pharmacokinetic profile of the 6-24 month group on a single 4 mg dose of montelukast oral granules was also compared to that of adults on 10 mg FCT. The AUCpop values were relatively similar in the two groups, while the Cmax values were 279 ng/ml and 514.4 ng/ml in adults and children respectively. 34 Yet another study indicated that a 5 mg chewable tablet administered once daily to children aged 6-14 years with asthma, resulted in a pharmacokinetic profile comparable to that of the clinically effective 10 mg FCT dose in adults. 35 
Dosages
Clinical trials indicated that the recommended daily dosage for the following age groups are: one 10 mg tablet to adults and adolescents 15 years of age and older; one 5 mg chewable tablet for pediatric patients 6 to 14 years of age; one 4 mg chewable tablet or one packet of 4 mg oral granules to pediatric patients 2 to 5 years of age; and one packet of 4 mg oral granules to pediatric patients 6 to 23 months of age. 27
Safety
The short-and long-term safety profiles of montelukast as a therapeutic agent in children aged 6 months to 14 years have been studied extensively. 33, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Serious adverse events, such as worsening asthma, appear to be rare 46 and all reported patients with drug overdoses recovered without sequelae. 46 Less serious side effects of montelukast occur uncommonly, but may include pharyngitis, dizziness, nausea, headache, diarrhea, fever, abdominal pain and rash. 33, 36, [41] [42] [43] [44] The incidence of adverse events associated with montelukast is comparable to those of other standard therapies for asthma in childhood and in some studies montelukast was equivalent to placebo. 40 Although FDA approval for montelukast has been obtained for children $2 years of age, safety data to date suggest that this agent may also be used for younger patients between the ages of 6 months and 2 years.
A recent meta-analysis concluded that the safety profile of montelukast at approved doses was acceptable and endorsed recommendations to administer this agent to children. 46 Good clinical practice still mandates that appropriate indications should exist for using montelukast in children and monitoring for adverse events should extend for the full duration of therapy. Based on current evidence, montelukast appears to be a safe drug for the pediatric population.
Although previous reports have linked montelukast to Churg-Strauss syndrome 47 and an increased suicide risk in adult patients, 48 no evidence currently available justifies similar concerns for children treated with this agent.
Efficacy and Clinical Trials
Viral-induced wheezing, a predominantly neutrophilmediated condition, is likely to be responsive to montelukast therapy. Available clinical trials, although of limited number, appear to support this contention as pre-school children with viral infections benefited from a 7 day course of therapy with this agent. 49 Increased production of cysteinyl leukotrienes in VIW may be effectively targeted by montelukast consequent to the well-recognized antagonistic effect of this agent on cysteinyl leukotriene receptors. Patients with intermittent asthma may suffer from viral-triggered exacerbations and LTRAs should be added to corticosteroid therapy for these patients if the initial clinical response is suboptimal.
Inhaled corticosteroids are widely accepted as the mainstay of therapy for children with chronic asthma. However, LTRAs may have a role in intermittent asthma as add-on or second-line therapy for children who do not respond to ICS or who are unable to use these agents. A 12 week, multi-centre, randomized, placebocontrolled, double-blind study evaluated the clinical efficacy of oral montelukast in 689 children 2 to 5 years of age with chronic persistent asthma. 50 Montelukast significantly improved each of the components of the composite symptom score over 12 weeks of treatment. For example, the reduction in the activity limitation score was 40% versus 22% for placebo (P , 0.001). During the 12 weeks of therapy, significantly fewer patients receiving montelukast, required corticosteroid rescue therapy to maintain asthma control. An additional study comparing fluticasone to montelukast in preschool children with asthma-like symptoms found both forms of therapy equally effective. 51 The 'PREVIA' Study 52 was designed to investigate the role of montelukast in preventing asthma exacerbations in children aged 2 to 5 years, with a history of episodic wheezing. Montelukast reduced the rate of asthma exacerbations by 32% (P , 0.001), as well as the requirement for oral corticosteroids (P = 0.024), compared to placebo.
A study was designed to determine the role of montelukast in children (2-14 years old) with intermittent asthma defined as a history of intermittent asthma with symptom-free intervals. 53 Montelukast or placebo were administered for a minimum of 7 days from the first symptoms of asthma or at the start of an URTI if this usually preceded asthma in that particular child. The montelukast group had 163 unscheduled health care resource utilizations for asthma compared to 228 in the placebo group (odds ratio 0.65; 95% CI, 0.47-0.89). Symptoms were reduced by 14% and days absent from school by 37% (P , 0.0001).
A study from Canada was designed to determine whether montelukast added to usual asthma therapy would reduce the number of days with increased asthma symptoms and unscheduled physician visits in children during the usual September (fall) epidemic of asthma exacerbations seen in that country. 54 Entry criteria included: i) 2-14 year olds; ii) physician-diagnosed asthma; iii) requirement for a rescue inhaler during the previous year; and iv) a history of asthma exacerbations associated with viral infections. Patients were instructed to take one tablet (montelukast or placebo) in the evening, commencing on 1st September, in addition to their usual asthma therapy. Children receiving montelukast experienced a 53% reduction in the number of days with increased asthma symptoms compared with placebo (3.9% vs. 8.3%) and a 78% reduction in unscheduled physician visits.
Exercise-induced bronchoconstriction (EIB) may also occur in children with underlying airway inflammation. Exercise is a recognized trigger for bronchoconstriction which is mediated by changes in airway temperature, humidity and osmolarity. Neutrophils and eosinophils are key cells implicated in EIB together with their lipid mediators (CysLTs, LTB 4 and PAF), reactive oxidant species, and proteases, 55 which are released when these inflammatory cells are activated. Montelukast has been shown in numerous clinical trials to effectively control EIB in children. 56, 57 A placebo-controlled, double-blinded, randomized two-period crossover study 58 was conducted in 27 children who had a mean baseline FEV 1 of 87% of predicted values and a maximal fall in FEV 1 of 35% after exercising on a treadmill for 6 min. None of the children was taking any controller medication for asthma. A washout of at least 4 days separated the montelukast 4 mg dose or placebo arms of the crossover study. Exercise challenge was performed 20-24 hr after the last dose of a 2 day treatment period with montelukast. Montelukast significantly attenuated exercise-induced bronchoconstriction, with more rapid return of the FEV 1 to near-basal values.
In a double-blinded, randomised parallel group design study of four weeks in a group of 6-12 year old asthmatic children, montelukast was found to provide significant protection against EIB in asthmatic children over the 4 week period with no tolerance to the bronchoprotective effect. 57
Patient Preference
Although ICS effectively control asthma, concern has been expressed regarding the negative effects of these agents on the growth of infants and children. 58 Montelukast is unlikely to retard growth and is thus a viable alternative, provided acceptable control of asthma symptoms is achieved. Montelukast may be preferred in those instances where very young children are unable to operate inhaler devices efficiently and parents have the option of an easy-to-administer oral preparation such as montelukast without resorting to systemic corticosteroids.
Place in Therapy
Montelukast has an important role in the management of intermittent asthma in children based on evidence from clinical trials and an appreciation of the broadspectrum anti-inflammatory properties of this agent. The potential benefits of montelukast in the therapy of children with intermittent asthma may include the following:
• Montelukast has broad-spectrum anti-inflammatory properties, affecting both eosinophilic and neutrophilic-mediated inflammation which may be useful for controlling both asthma 59 and viral-induced airway disorders, 60, 61 respectively.
• Many children with asthma have concurrent rhinosinusitis which has been shown to respond to montelukast. 62 Furthermore, effective treatment of upper airway conditions often improves asthma control. • The ease of oral administration of montelukast may improve compliance in pre-school children. • Concerns have been expressed regarding the adverse effects of inhaled corticosteroids 58 and for these children montelukast may provide a useful alternative. • The excellent safety profile of montelukast in children must be considered when weighing the risks and benefits of various therapeutic strategies for asthma.
Conclusions
Montelukast possesses broad-spectrum antiinflammatory properties which may be particularly useful in down-regulating both neutrophil-and eosinophil-mediated pro-inflammatory activity inherent in the pathogenesis of viral-induced wheeze and asthma, respectively. However, the extended anti-inflammatory spectrum of montelukast has yet to be fully incorporated into both clinical guidelines and personalized medicine for children with inflammatory airway disorders. Future clinical trials should clearly define the optimal indications for this agent in treating acute exacerbations and chronic asthma.
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